University of Texas MD Anderson Cancer Center
Houston, TX
Dr. Sherry is a PGY-5 resident in radiation oncology at MD Anderson Cancer Center. He completed an undergraduate degree at the University of North Carolina at Chapel Hill and medical school at Vanderbilt University. His professional interests include ablative radiotherapy in metastatic disease, the immune response to radiotherapy, functional stereotactic radiosurgery, data science, and clinical trials methodology. His academic career goals are to integrate modern radiotherapy and molecular therapy in novel clinical trials guided by disease biology in addition to traditional clinicopathologic and radiologic factors. Specifically, he is interested in the interplay between immune-oncology and ablative radiotherapy. During medical school, he studied the use of high-dose modern stereotactic radiation/radiosurgery for the treatment of various types of cancer and benign conditions. He also analyzed the impact of radiotherapy on the systemic immune response in breast cancer and esophageal cancer. During residency, he has focused on the interaction between the immune system and ablative radiotherapy in oligometastasis. He has also worked on clinical trials methodology through empirical analyses of phase III randomized controlled trials, including studies of prognostic covariates, endpoint selection, and subgroup analyses.
Disclosures:
2601 - Off-Protocol Radiotherapy in Phase III Metastatic Solid Tumor Trials
Monday, September 30, 2024
10:45 AM – 12:00 PM ET